Plenadren
ApprovedSmall molecule
Plenadren is one of 12 small molecule programs targeting Fatigue. It is currently in Approved.
2
Indications
3
Total Trials
0
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Adrenal Insufficiency
#DrugCompanyPhaseTrials
1Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Rayos
RRoxane Laboratories
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Dehydroepiandrosterone
IInflabloc Pharmaceuticals
Phase 3
Plenadren
UUniversity of Roma La Sapienza
Approved
Fludrocortisone 0.1 Milligrams (mg)
GGanin Fertility Center
Approved
Mifeprex
DDanco
Phase 2
Infacort
NNeurocrine UK Limited
Phase 3
Megace
Bristol-Myers SquibbPreclinical
Chronocort
NNeurocrine UK Limited
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Adrenal insufficiency1 trial
Fatigue1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Plenadren. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- UUniversity of Roma La Sapienza